Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
Volume 10, Issue 6, Pages 1562-1568Publisher
ELSEVIER
DOI: 10.1016/j.jaip.2022.02.022
Keywords
Acute asthma; Children; Cost-effectiveness; Inhaled corticosteroids
Categories
Ask authors/readers for more resources
This study compares the cost-effectiveness of using short-acting beta(2)-agonists (SABAs) alone versus using SABAs plus inhaled corticosteroids (ICS) in children with mild intermittent asthma. The results show that using SABAs plus ICS is more cost-effective, resulting in lower treatment costs and a higher probability of not requiring prednisone.
BACKGROUND: Although the efficacy of the as-needed use of short-acting beta(2)-agonists (SABAs) plus inhaled corticosteroids (ICS) for treating children with mild intermittent asthma has been demonstrated, evidence of its cost-effectiveness is scarce. OBJECTIVES: The aim of the present study was to compare the cost-effectiveness of the as-needed use of SABAs alone versus the as-needed use of SABAs plus ICS in children 5 to 11 years old with mild intermittent (step 1) asthma but suffering from an exacerbation of asthma symptoms. METHODS: A decision-analysis model was adapted. Effectiveness parameters were obtained from a randomized clinical trial. Cost data were obtained from hospital bills and from the national manual of drug prices in Colombia. The study was carried out from the perspective of the national health care system in Colombia. The main outcome of the model was a first course of prednisone for an asthma exacerbation (AE). RESULTS: Compared with the use of SABAs alone, the as-needed use of SABAs plus ICS was associated with lower overall treatment costs (US$17.99 vs US$27.94 mean cost per patient) and a higher probability of a lack of a requirement for a first course of prednisone (0.6500 vs 0.5100), thus showing dominance. CONCLUSIONS: In Colombia, compared with the use of albuterol alone, the use of beclomethasone dipropionate added to albuterol as needed for symptom relief is cost-effective in children 5 to 11 years old with mild intermittent (step 1) asthma, because it involves a higher probability of a lack of a requirement for prednisone for AE at lower total treatment costs. (C) 2022 American Academy of Allergy, Asthma & Immunology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available